<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03172377</url>
  </required_header>
  <id_info>
    <org_study_id>NL58948.091.16</org_study_id>
    <secondary_id>848015002</secondary_id>
    <secondary_id>2016-003321-42</secondary_id>
    <nct_id>NCT03172377</nct_id>
  </id_info>
  <brief_title>Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients</brief_title>
  <acronym>LADI</acronym>
  <official_title>Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Crohn's disease is a chronic inflammatory bowel disease. This disease can be treated with,
      among other things, biologicals such as adalimumab. Patients use adalimumab for a long time
      to maintain remission and to prevent relapse of the bowel inflammation. The disadvantages of
      this therapy are the high price and side effects (such as the higher risk of infection).

      Currently, adalimumab is given every 2 weeks, by injection under the skin. The optimal time
      between two injections has never been investigated before. Prior research in patients with
      rheumatoid arthritis shows that disease remission can be maintained with longer
      injection-intervals. Our hypothesis is that this is the same for Crohn's disease patients.
      Our aim is to show non-inferiority of extending the adalimumab dosing interval, under strict
      disease monitoring in Crohn's disease patients in sustained (&gt;12 months) clinical remission,
      compared to standard care.

      During the trial,174 patients with stable Crohn's disease will be divided into 2 groups. One
      group continues adalimumab injections with the same 2-week interval. And the other group will
      incrementally extend the interval to 4 weeks, under strict disease monitoring. If a step-down
      leads to recurrence of disease activity patients will return to the preceding effective
      dosing interval. Thus, we will investigate whether, and for whom, it is safe to extend the
      adalimumab injection interval.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale

      Adalimumab is both an effective induction and maintenance therapy for Crohn's disease (CD).
      Due to the risk of side effects (infections, injection reaction) and high costs, an extension
      of the injection interval is an attractive option. However, this strategy has not been
      evaluated yet in a randomized controlled trial in CD patients.

      Objective

      To assess non-inferiority of extending the adalimumab dosing interval, under strict disease
      monitoring in CD patients in sustained (&gt;12 months) clinical remission, compared to standard
      care.

      Study design

      Multicenter, randomized controlled, open label non-inferiority trial, with two treatment
      arms.

      Study population

      Crohn's disease patients, in sustained clinical remission on adalimumab maintenance therapy.

      Intervention

      Intervention arm: The adalimumab injection interval during maintenance therapy (40 mg per 2
      weeks) will be extended through a stepwise disease activity guided manner to 3 weeks and
      subsequently - after 24 weeks - to 4 weeks. If a step-down leads to recurrence of disease
      activity patients will return to the preceding effective dosing interval.

      Control arm: patients will continue adalimumab treatment following their usual dose and
      schedule. Treatment decisions are made at the discretion of the treating physician who will
      be blinded for the results of additional assessments beyond standard of care.

      Main study parameters/endpoints

      Primary outcome: The difference in cumulative incidence of pre-defined persistent flares
      between the dose reduction and usual care groups at 48-week follow-up.

      A persistent flare is defined as increased inflammatory markers (FC &gt;250 μg/g and/or CRP ≥10
      mg/L) combined with patient-reported symptoms (HBI ≥ 5), persisting for &gt;8 weeks despite dose
      escalation of adalimumab.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, randomized controlled, open label non-inferiority trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference in cumulative incidence of pre-defined persistent flares between the dose reduction and usual care groups.</measure>
    <time_frame>From the date of randomization up to week 48.</time_frame>
    <description>A persistent flare is defined as increased inflammatory markers (FC &gt;250 μg/g and/or CRP ≥10 mg/L) combined with patient-reported symptoms (HBI ≥ 5), persisting for &gt;8 weeks despite dose escalation of adalimumab.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Crohn Disease in Remission</condition>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lengthening adalimumab dosing interval: The adalimumab injection interval during maintenance therapy (40 mg sc / 2 weeks) will be extended through a stepwise disease activity guided manner to 3 weeks and subsequently - after 24 weeks - to 4 weeks. If a step-down leads to recurrence of disease activity patients will return to the preceding effective dosing interval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard care: Patients will continue adalimumab treatment following their usual dose and schedule. Treatment decisions are made at the discretion of the treating physician who will be blinded for the results of additional assessments beyond standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lengthening adalimumab dosing interval</intervention_name>
    <description>Lengthening adalimumab dosing interval from 2 weeks to 3 weeks and -later- to 4 weeks.</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>Lengthening Humira dosing interval</other_name>
    <other_name>Longer adalimumab interval</other_name>
    <other_name>Longer Humira interval</other_name>
    <other_name>Adalimumab dose reduction</other_name>
    <other_name>Humira dose reduction</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of colonic and/or distal ileal CD

          -  Sustained steroid-free clinical remission for &gt;12 months whilst being treated with
             adalimumab at a stable dose

          -  Adalimumab dosed at 40 mg sc every 2 weeks

          -  Full clinical response and disease control, all three criteria below need to be
             fulfilled prior to enrollment:

               -  Absence of active inflammatory intestinal or extra-intestinal symptoms, as judged
                  by both patient and physician

               -  Fecal calprotectin (FC) &lt; 150 μg/g and CRP &lt;10 mg/L

               -  Harvey Bradshaw Index (HBI) &lt;5

        Exclusion Criteria:

          -  Absence of written informed consent

          -  Concomitant corticosteroid usage

          -  Need for IBD-related surgery

          -  Actively draining peri-anal fistula

          -  Pregnancy or lactation

          -  Other significant medical conditions that might interfere with this study (such as
             current/recent malignancy, immunodeficiency syndromes and psychiatric illness)

          -  Impossibility to measure outcomes, e.g. planned relocation, language issues, short
             life expectancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Hoentjen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. dr. van der Woude, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Smits, MD</last_name>
    <phone>0031248186626</phone>
    <email>lisa.smits@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Renske Pauwels, MD</last_name>
    <phone>0031107034513</phone>
    <email>r.pauwels@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rijnstate Ziekenhuis</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <zip>PO box 9555, 6800 TA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Horjus, MD, PhD</last_name>
      <email>CHorjus-TalaburHorje@rijnstate.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Smits, MD</last_name>
      <phone>0031248186626</phone>
      <email>lisa.smits@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Radboud university medical center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>PO box 9101, 6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Smits, MD</last_name>
      <phone>0031248186626</phone>
      <email>lisa.smits@radboudumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Dr. Hoentjen, MD, PhD</last_name>
      <phone>0031248186626</phone>
      <email>frank.hoentjen@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>'s Hertogenbosch</city>
        <state>Noord-Brabant</state>
        <zip>PO box 90153, 5200 ME</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Drs. Römkens, MD</last_name>
      <email>t.romkens@jbz.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Smits, MD</last_name>
      <phone>0031248186626</phone>
      <email>lisa.smits@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <state>Noord-Brabant</state>
        <zip>PO box 90157, 4800 RL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Bodelier, MD, PhD</last_name>
      <email>ABodelier@amphia.nl</email>
    </contact>
    <contact_backup>
      <last_name>Renske Pauwels, MD</last_name>
      <phone>0031107034513</phone>
      <email>r.pauwels@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Bernhoven</name>
      <address>
        <city>Uden</city>
        <state>Noord-Brabant</state>
        <zip>PO box 707, 5400 AS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>VU Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. De Boer, MD, PhD</last_name>
      <email>KHN.deBoer@vumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Smits, MD</last_name>
      <phone>0031248186626</phone>
      <email>lisa.smits@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Ziekenhuis</name>
      <address>
        <city>Dordrecht</city>
        <state>Zuid-Holland</state>
        <zip>PO box 444, 3300 AK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Beukers, MD, PhD</last_name>
      <email>r.beukers@asz.nl</email>
    </contact>
    <contact_backup>
      <last_name>Renske Pauwels, MD</last_name>
      <phone>0031107034513</phone>
      <email>r.pauwels@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Franciscus Gasthuis &amp; Vlietland</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>PO box 10900, 3004 BA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. West, MD, PhD</last_name>
      <email>R.West@Franciscus.nl</email>
    </contact>
    <contact_backup>
      <last_name>Renske Pauwels, MD</last_name>
      <phone>0031107034513</phone>
      <email>r.pauwels@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>PO box 2040, 3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renske Pauwels, MD</last_name>
      <phone>0031107034513</phone>
      <email>r.pauwels@erasmusmc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Prof. dr. van der Woude, MD, PhD</last_name>
      <email>c.vanderwoude@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ikazia Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>PO box 5009, 3008 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Ouwendijk, MD, PhD</last_name>
      <email>rjth.ouwendijk@ikazia.nl</email>
    </contact>
    <contact_backup>
      <last_name>Renske Pauwels, MD</last_name>
      <phone>0031107034513</phone>
      <email>r.pauwels@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>PO box 85500, 3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Oldenburg, MD, PhD</last_name>
      <email>boldenbu@umcutrecht.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Smits, MD</last_name>
      <phone>0031248186626</phone>
      <email>lisa.smits@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://www.zonmw.nl/nl/over-zonmw/innovatie-in-de-zorg/programmas/project-detail/goed-gebruik-geneesmiddelen/lengthening-adalimumab-dosing-interval-in-quiescent-crohns-disease-patients-the-ladi-study/</url>
    <description>Dutch organisation for healthcare research and innovation (ZonMW)</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2017</study_first_submitted>
  <study_first_submitted_qc>May 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>August 23, 2017</last_update_submitted>
  <last_update_submitted_qc>August 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adalimumab</keyword>
  <keyword>anti-TNF</keyword>
  <keyword>Humira</keyword>
  <keyword>interval lengthening</keyword>
  <keyword>dosing interval</keyword>
  <keyword>inflammatory bowel disease</keyword>
  <keyword>antidrug antibodies</keyword>
  <keyword>trough levels</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>cost-effectiveness</keyword>
  <keyword>dose reduction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

